Sequence: Poly(γ-(4-vinylbenzyl)-L-glutamate) derivative; DP ~206 (helical polypeptide)
| Experiment Id | EXP000235 |
|---|---|
| Paper | Suppression of Hepatic Inflammation via Systemic siRNA Delivery by Membrane-Disruptive and Endosomol |
| Peptide | PPABLG |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | PPABLG/PAOBLG-MPA/siRNA = 20/2/1 (w/w/w) |
| Rna Concentration | ~0.2 µg/mL (in vitro) |
| Mixing Ratio | 20/2/1 (PPABLG/PAOBLG-MPA/siRNA, w/w/w) |
| Formulation Format | hybrid polypeptide nanoparticle (HNP) |
| Formulation Components | PPABLG + PAOBLG-MPA + siRNA |
| Size Nm | 100.00 |
| Zeta Mv | 30.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | RAW 264.7 macrophages; murine PECs |
| Animal Model | |
| Administration Route | |
| Output Type | gene knockdown |
| Output Value | ~90% inhibition of TNF-α production |
| Output Units | |
| Output Notes | Helicity-dependent membrane pore formation enables direct translocation and endosomal escape |
| Toxicity Notes | Negligible cytotoxicity at working doses |
| Curation Notes |